Photodynamic Therapy of Corneal Neovascularization with Verteporfin

Fossarello, Maurizio; Peiretti, Enrico; Zucca, Ignazio Alberto; Serra, A.

doi:10.1097/00003226-200307000-00018

Cited by 64 publications

(29 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pathological angiogenesis is also thought to play an important role in corneal allografts by facilitating the exposure of antigens in the donor cornea to the immune system [2]. Many medical and surgical treatments, including use of steroids [3][4][5], use of non-steroidal anti-inflammatory agents [6][7][8], argon laser photocoagulation [9], photodynamic therapy [1,10], and limbal stem cell transplantation [11,12], have been effective in inhibiting corneal neovascularization in both animal and human models. However, further investigation is needed to determine whether anti-angiogenic therapy is effective for treatment against actively growing and established corneal neovascularization.…”

Section: Introductionmentioning

confidence: 99%

“…The effect of rAAV-CMV-endostatin on experimentally induced corneal angiogenesis was evaluated by comparing the extent of neovascularization with that in the control AAV-CMV-EGFP or PBS groups (Figure 4). Based on this grading system, the average number of eyes exhibiting the different degrees of neovascularization at different time points (7,10,14, and 21 days after cauterization; see Table 1) was evaluated. Here, the rAAV-CMV-EGFP treatment group showed a significantly higher occurrence of severe neovascularization than the rAAV-CMV-endostatin treatment group.…”

Section: Introduction Of Raav-endostatin Inhibits Neovascularization mentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model

Lai

Xiao

2007

J Biomed Sci

View full text Add to dashboard Cite

The use of a recombinant adeno-associated viral (rAAV) vector carrying endostatin gene as an anti-angiogenesis strategy to treat corneal neovascularization in a mouse model was evaluated. Subconjunctival injection of recombinant endostatin-AAV was used to examine the inhibition of corneal neovascularization induced by silver nitrate cauterization in mice. The results showed that gene expression in corneal tissue was observed as early as 4 days after gene transfer and stably lasted for over 8 months with minimal immune reaction. Subconjunctival injection of a high-titer rAAV-endostatin successfully inhibited neovascularization. Immunohistchemistry staining of CD 31 and endostatin showed that the treatment significantly inhibits angiogenesis in cornea. We concluded that the rAAV was capable of directly delivering genes to the ocular surface epithelium by way of subconjunctival injection and was able to deliver sustained, high levels of gene expression in vivo to inhibit angiogenesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introduction Of Raav-endostatin Inhibits Neovascularization mentioning

confidence: 99%

Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model

Lai

Xiao

2007

J Biomed Sci

View full text Add to dashboard Cite

show abstract

“…[251][252][253] The largest, by Yoon et al, 253 used verteporfin in 18 eyes with established CNV secondary to a number of etiologies, although principally LK (8 of 18) and PK (5 of 18). At the 12-month follow-up, 9 of 18 were classified as have completely occluded; 5 of 18 partially occluded; 2 of 18 recanalized; and 2 were regarded as failures.…”

Section: Photodynamic Therapymentioning

confidence: 99%

“…There were no systemic or ocular complications noted with the dye. The disadvantages of verteporfin include its high cost, 252,253 photosensitivity reactions, and infusion-related back pain. 257 Fossarello et al, 252 noted that the costs may be greatly reduced if subconjunctival verteporfin may be proven to be effective and safe as it has been shown to be for the treatment of pterygia.…”

Section: Photodynamic Therapymentioning

confidence: 99%

Treatments for Corneal Neovascularization: A Review

Gupta¹,

Illingworth²

2011

Cornea

View full text Add to dashboard Cite

Corneal neovascularization (CNV) may be a physiological response to various stimuli, but a chronic and persistent upregulation of neoangiogenesis can result in pathological CNV. Pathological blood vessels are immature and lack structural integrity, predisposing the cornea to lipid exudation, inflammation, and scarring. CNV can therefore become a potentially blinding condition. In this review, we frame CNV in an epidemiological perspective, consider risk factors for CNV, provide an overview of CNV pathogenesis, and consider the impact of CNV on corneal transplantation. We consider treatments that are of largely historical interest, before reviewing contemporary medical and surgical treatments. Within medical treatments, we report on steroids, nonsteroidal anti-inflammatory agents, antivascular endothelial growth factor agents, and cyclosporine. Within surgical treatments, we report on the use of lasers, photodynamic therapy, superficial keratectomy, and diathermy/cautery-based treatments.

show abstract

“…In addition, PDT has proven especially useful in ophthalmology and has been evaluated in the treatment of ocular tumours (Lingua 1991;Kim et al 1996), and choroidal (Woodburn et al 2002) and corneal (Fossarello et al 2003;Brooks et al 2004) neovascularization. Photodynamic therapy using verteporfin i.v.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic treatment in a rabbit model of glaucoma surgery

Stasi

Paccione

Bianchi

et al. 2006

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

. Purpose: To evaluate the safety and efficacy of postoperative verteporfin photodynamic treatment as an adjunct to glaucoma experimental filtration surgery in rabbits. Methods: Dutch belted (n = 15) rabbits underwent full thickness sclerectomy in one eye. The experimental group (group 1, n = 7) underwent i.v. injection of verteporfin and subsequent photoactivation at the operative site on postoperative day 1 (POD 1). Control groups of animals received either light exposure (group 2, n = 4) or verteporfin (group 3, n = 2), or no intervention (group 4, n = 2). Intraocular pressure (IOP) was measured prior to the procedure (POD 0) and daily thereafter for the first week after sclerectomy (PODs 1−7) and every other day for the second week (PODs 9, 11, 13, 15). Percentage IOP reductions of operated over contralateral control eyes were compared among the various groups. Success rates (percentage IOP reduction > 15%) were also compared between the experimental and control groups. Eyes were histologically examined for evaluation of fibrosis. Results: Rabbits in the experimental group (group 1) had a mean ± SEM percentage IOP reduction of 25 ± 3% during the follow‐up period. In contrast, groups 2, 3 and 4 had IOP reductions of 4 ± 5%, 12 ± 7% and 4 ± 6%, respectively (p < 0.005, anova among all four groups). Successful IOP reduction (≥ 15%) over the contralateral eye at POD 15 was achieved in six of seven experimental animals, but only in one of eight control animals (p < 0.02, chi‐squared test). Bleb failure occurred significantly earlier in the control eyes compared with eyes receiving PDT (p < 0.003, log rank test). Blebs in the experimental group differed from those in the control groups histologically, lacking significant collagen deposition in the area of the sclerostomy. Conclusions: Wound healing in glaucoma surgery may be successfully modulated postoperatively using photodynamic therapy with i.v. administered photosensitizer.

show abstract

Photodynamic Therapy of Corneal Neovascularization with Verteporfin

Abstract: PDT with verteporfin is an effective and safe procedure indicated for patients with corneal neovascularization; however, multiple sessions may be required.

Cited by 64 publications

References 12 publications

Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model

Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model

Treatments for Corneal Neovascularization: A Review

Photodynamic treatment in a rabbit model of glaucoma surgery

Contact Info

Product

Resources

About